慢性炎症性肠病患者的认知功能障碍和情绪障碍查:前性病例对照研究的协议
Oliviu Florentiu Sarb1, Vitalie Vacaras1, Adriana Sarb2
1Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
JMIR research protocols
|October 12, 2023
概括
患有炎症性肠病 (IBD) 的患者可能会出现认知能力下降. 这项研究探讨了肠-大脑轴 (GBA) 和血液生物标志物作为IBD患者轻度认知障碍 (MCI) 的潜在预测因素.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 生物标志物研究 生物标志物研究
背景情况:
- 炎症性肠病 (IBD) 可能与轻度认知障碍 (MCI) 和阿尔茨海默氏病 (AD) 的增加率有关.
- 肠-大脑轴 (GBA),全身炎症和药物副作用被假设为IBD中MCI的贡献.
- 特定的血液生物标志物,如血清粉样蛋白A (SAA),同氨酸 (Hcy),来自大脑的神经营养因子 (BDNF) 和S100结合蛋白B (S100B) 可能表明认知状态.
研究的目的:
- 研究肠-大脑轴 (GBA) 相互作用在炎症性肠病 (IBD) 患者中轻度认知障碍 (MCI) 的发展中的作用.
主要方法:
- 一项涉及100名IBD患者和100名匹配健康对照者的病例控制研究.
- 综合检查包括认知测试 (例如,MoCA,Trail Making Test) 和查抑郁,压力和焦虑.
- 血清生物标志物 (SAA,Hcy,S100B,BDNF) 的分析和48个月的随访.
主要成果:
- 目前正在进行数据收集;预先分析计划于2024年4月进行.
- 预期的发现包括IBD患者的认知分数较低,疾病持续时间和认知障碍之间的相关性,以及IBD组中更高的心理痛苦.
- 预计血清生物标志物水平与认知得分相关,可能预测MCI或痴呆症.
结论:
- 肠-大脑轴 (GBA) 相互作用,炎症和药物影响可能导致IBD患者的MCI和AD.
- 血清生物标志物显示出作为MCI在这个人群中发展的具有成本效益的预测因素的前景.
关键词:
IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD情感情绪障碍 情绪障碍焦虑是一种焦虑.血液 血液 血液 血液肠道 肠道 肠道 肠道认知 认知 认知有关认知性的认知.认知功能障碍 认知功能障碍痴呆症 痴呆症是一种痴呆症.抑郁 抑郁症 抑郁症 抑郁症 是一种抑郁症是一种严重的抑郁.在胃肠道上,胃肠道.肠 - 大脑 肠 - 大脑肠大脑轴 肠大脑轴这是一种炎症炎症炎症炎症.这是一种炎症性炎症.炎症性肠病是一种炎症性肠病.情绪 情绪 情绪 情绪这是一种神经缩性神经营养.蛋白质蛋白质是一种蛋白质蛋白质.蛋白质是一种蛋白质.血液中的血清是血清.压力就是压力,压力就是压力.
相关概念视频
01:17Chronic Bowel Disorders: Introduction
460
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
460
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
339
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
339
01:30Inflammatory Bowel Disease II: Crohn's Disease
264
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
264
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
170
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
170
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
196
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
196
01:29Inflammatory Bowel Disease IV: Pharmacological Management
135
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
135